Clinical Trials
18 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT06910657 2026-03-02
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Phase 1 Recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06943521 2025-12-11
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Phase 1/2 Recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT05012397 2024-10-17
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Phase 2 Terminated
NCT02549937 2024-07-10
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT01271959 2012-10-05
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Precision Therapeutics
Terminated
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed